Overview

Efficacy and Safety of BG00012 in MS

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Determine the efficacy,safety, and tolerability of BG00012 in MS patients.
Phase:
Phase 2
Details
Lead Sponsor:
Biogen
Treatments:
Dimethyl Fumarate